Actively Recruiting
iMmune SignAtures and Clinical outComes in AP
Led by Ohio State University · Updated on 2025-08-22
198
Participants Needed
5
Research Sites
251 weeks
Total Duration
On this page
Sponsors
O
Ohio State University
Lead Sponsor
U
University of Pittsburgh
Collaborating Sponsor
AI-Summary
What this Trial Is About
The MoSAIC study is a prospective, observational study designed to develop an early prediction tool for severe acute pancreatitis (SAP) and define a distinct immunologic profile compared to moderate acute pancreatitis (MAP). The aims are to validate a new multi-cytokine panel for early prediction of SAP and to identify the specific immune cells that correspond with cytokine signatures in early acute pancreatitis to characterize the immune pathways driving the development of SAP. Participants will provide blood samples and complete patient surveys and interviews within 36 hours of hospital presentation, at 48 hours, and hospital day 7 (if admitted). Data on hospital stay, medical history, clinical course, and severity of disease will be collected.
CONDITIONS
Official Title
iMmune SignAtures and Clinical outComes in AP
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-75 years at the time of enrollment
- Diagnosis of acute pancreatitis (AP) according to the revised Atlanta criteria
- Participant is approached by the research team within 36 hours of hospital presentation
- Participant fully understands and agrees to participate in all study aspects, including informed consent, interviews, data forms, and biospecimen collection
You will not qualify if you...
- Definite chronic pancreatitis at enrollment confirmed by CT, MRI, or MRCP imaging
- Post-ERCP acute pancreatitis expected to require less than 48 hours hospitalization
- Pancreatic tumors including ductal adenocarcinoma, neuroendocrine tumors, and metastasis
- Confirmed or suspected cystic tumor causing main pancreatic duct dilation or acute pancreatitis
- Prior pancreatic surgery including distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, or Frey procedure
- Severe systemic illness posing risk or confounding outcomes, including solid organ transplant history, AIDS, active cancer treatment within 12 months (except non-melanoma skin cancer), chronic kidney disease with eGFR <30 or dialysis, cirrhosis, or life expectancy less than 12 months
- Known pregnancy at enrollment
- Incarceration
- Any other condition that compromises participant safety or study integrity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
University of Southern California
Los Angeles, California, United States, 90033
Not Yet Recruiting
2
University of Illinois Chicago
Chicago, Illinois, United States, 60612
Not Yet Recruiting
3
The Ohio State University
Columbus, Ohio, United States, 43210
Actively Recruiting
4
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Not Yet Recruiting
5
Benaroya Research Institute
Seattle, Washington, United States, 98101
Not Yet Recruiting
Research Team
Z
Zoe Krebs, BA
CONTACT
S
Samantha Terhorst, MS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here